Harold Koendgen

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

Ludwig Kappos, Jerry S. Wolinsky, Gavin Giovannoni et al. · JAMA Neurology · 2020 · 562 citations · Full text

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Pei‐Ran Ho, Harold Koendgen, Nolan Campbell et al. · The Lancet Neurology · 2017 · 310 citations

Systemic Diseases, Disease Progression, Autoimmune Disease +12

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Stephen L. Hauser, Ludwig Kappos, Xavier Montalbán et al. · Neurology · 2021 · 166 citations · Full text

Five years of ocrelizumab in relapsing multiple sclerosis

Stephen L. Hauser, Ludwig Kappos, Douglas L. Arnold et al. · Neurology · 2020 · 150 citations · Full text

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Jerry S. Wolinsky, Douglas L. Arnold, Bruno Brochet et al. · The Lancet Neurology · 2020 · 142 citations

Disease Progression, Medicine, Clinical Neurology +8